Acute Coronary Syndrome in the Era of SARS-CoV-2 Infection: A Registry of the French Group of Acute Cardiac Care

Athanasios Koutsoukis, MD,a,b Clément Delmas, MD,c François Roubille, MD, PhD,d Laurent Bonello, MD, PhD,e Guillaume Schurtz, MD,f Stéphane Manzo-Silberman, MD,g Etienne Puymirat, MD, PhD,h Meyer Elbaz, MD,i Frédéric Bouisset, MD,i Pierre-Alain Meunier, MD,i Fabien Huet, MD,d Franck Paganelli, MD, PhD,e Marc Laine, MD,c Gilles Lemesle, MD, PhD,f Nicolas Lamblin, MD, PhD,f Patrick Henry, MD, PhD,g Victoria Tea, MD,h Romain Gallet, MD, PhD,a,b Emmanuel Teiger, MD, PhD,a,b Raphaëlle Huguet, MD,a,b Damien Fard, MD,a,b and Pascal Lim, MD, PhD,a,b

a Univ Paris Est Créteil, INSERM, IMRB, Créteil, France
b AP-HP, Hôpital Universitaire Henri-Mondor, Service de Cardiologie, Créteil, France
c Intensive Cardiac Care Unit, Rangueil University Hospital, Toulouse, France
d PhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, CHU de Montpellier, France
e Aix-Marseille Univ, Intensive care unit, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille France, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille France, Centre for CardioVascular and Nutrition research (C2VN), INSERM a263, INRA a260, Marseille, France
f Intensive Care Unit, Institut Coeur Poumon, Centre Hospitalier de Lille, Lille, France
g Department of Cardiology, Lariboisière hospital, Assistance Publique - Hôpitaux de Paris, Paris University, INSERM UMRS i42, Paris, France
h AP-HP, Hôpital Européen Georges Pompidou (HEGP), Department of Cardiology, Paris France, Université de Paris, Paris, France
i Cardiology department, Rangueil University Hospital, Toulouse, France

ABSTRACT

Background: In this study, we aimed to report clinical characteristics and outcomes of patients with and without SARS-CoV-2 infection who were referred for acute coronary syndrome (ACS) during the peak of the pandemic in France.

Since December 2019, the world has been facing an outbreak of an emerging coronavirus SARS-CoV-2 (severe acute respiratory syndrome related to coronavirus-2) with a wide spectrum of presentations and associated mortality of 2%-3%.1,2 The disease is characterized first by a viral replication phase (early infection) followed by a host inflammatory response phase related to a cytokine storm, which might be accompanied by thrombotic events. For example, pulmonary embolism is frequent among patients with SARS-CoV-2-associated pneumonia, with predominantly bilateral vascular defects, which might suggest a prothrombotic state.3,4 Data in the literature indicate a cardiac involvement in 20% of severe SARS-CoV-2 infections, which translates into worsened outcome. Underlying pathophysiological mechanisms remain poorly understood and might involve coronary thrombosis and/or acute viral and immunoinflammatory myocarditis.5-7 The recent case series by Bangalore et al., in which 18 patients presented with SARS-CoV-2 infection and ST-segment elevation on electrocardiogram, showed a surprisingly high inhospital mortality rate (ie, 72%), contrary to the reported event rates for acute coronary syndrome (ACS) in recent literature (between 4% and 12%).5,8 Also in the case series of
Methods: We included all consecutive patients referred for ST-elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) during the first 3 weeks of April 2020 in 5 university hospitals (Paris, south, and north of France), all performing primary percutaneous coronary intervention.

Results: The study included 237 patients (67 ± 14 years old; 69% male), 116 (49%) with STEMI and 121 (51%) with NSTEMI. The prevalence of SARS-CoV-2-associated ACS was 11% (n = 26) and 11 patients had severe hypoxemia on presentation (mechanical ventilation or nasal oxygen > 6 L/min). Patients were comparable regarding medical history and risk factors, except a higher prevalence of diabetes mellitus in SARS-CoV-2 patients (53.8% vs 25.6%; P = 0.003). In SARS-CoV-2 patients, cardiac arrest on admission was more frequent (26.9% vs 6.6%; P < 0.001). The presence of significant coronary artery disease and culprit artery occlusion in SARS-CoV-2 patients respectively, was 92% and 69.4% for those with STEMI, and 50% and 15.5% for those with NSTEMI. Percutaneous coronary intervention was performed in the same percentage of STEMI (84.6%) and NSTEMI (84.8%) patients, regardless of SARS-CoV-2 infection, but no-reflow (19.2% vs 3.3%; P < 0.001) was greater in SARS-CoV-2 patients. In-hospital death occurred in 7 SARS-CoV-2 patients (5 from cardiac cause) and was higher compared with noninfected patients (26.9% vs 6.2%; P < 0.001).

Conclusions: In this registry, ACS in SARS-CoV-2 patients presented with high a percentage of cardiac arrest on admission, high incidence of no-reflow, and high in-hospital mortality.

Stefanini et al. from Italy, in approximately 40% of patients with COVID-19 and ST-elevation myocardial infarction (STEMI), a culprit lesion was not identifiable using coronary angiography. Therefore, we aimed to investigate the clinical characteristics and outcome of patients with myocardial infarction and SARS-CoV-2 infection among French hospitals during the peak of the SARS-CoV-2 pandemic in France.

Methods

Population

All patients referred for ACS to the cardiac catheterization laboratory during the first 3 weeks of April (from April 1-22, 2020) were screened. All patients with myocardial infarction (STEMI or non-STEMI [NSTEMI]) who underwent coronary angiogram were included in the study. Myocardial infarction was defined as rise and/or fall of troponin values with at least 1 value above the 99th percentile and clinical evidence of acute myocardial ischemia (symptoms of myocardial ischemia, new ischemic electrocardiogram changes, development of pathological Q waves, imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality in a pattern consistent with an ischemic etiology, or identification of a coronary thrombus using coronary angiography). STEMI was diagnosed when ST-segment elevation ≥ 1 mm was seen in at least 2 contiguous leads in any location on the index or qualifying electrocardiogram, or when presumed new left bundle-branch block or documented new Q waves were observed. In the absence of ST-segment elevation, patients who met the inclusion criteria were considered to have NSTEMI. We excluded patients medically treated without coronary angiogram documentation. The study was conducted by the French Group of Cardiac Intensive Care Network in accordance with European Society of Cardiology guidelines and French law. Data were collected from 3 regions of France with high (Paris, n = 2 centres), moderate (north of France, n = 1 centre), and low (south of France, n = 2 centres) prevalence of SARS-CoV-2 infection. Investigator centres were 5 university hospitals with high experience in percutaneous coronary intervention (PCI). Although all consecutive patients were screened, data collection was retrospective.
Acute Coronary Syndrome and SARS-CoV-2 Infection

Koutsoukis et al. 313

Diagnosis of SARS-CoV-2 during ACS

SARS-CoV-2 infection status was systematically investigated in all suspected cases. A first clinical evaluation was conducted by the emergency structure (emergency department, French emergency medical system [SAMU] or in the cardiac intensive care unit) before admission in the catheterization laboratory. Criteria for suspecting SARS-CoV-2 infection were: (1) any recent or current clinical sign compatible with SARS-CoV-2 infection (fever, dyspnea, cough, flu symptoms); and (2) a recent contact (<15 days) with a patient with a confirmed SARS-CoV-2 infection. In patients with suspected infection, reverse transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal sample was performed. Chest computed tomography imaging was performed at the discretion of the attending physician in association with RT-PCR to confirm or exclude the diagnosis of SARS-CoV-2 infection. Only patients with definite infection diagnosis according to RT-PCR or chest computed tomography imaging were included in the "ACS with SARS-CoV-2 infection" group.

Management of SARS-CoV-2 infection

Specific treatment of SARS-CoV-2 infection was not standardized and depended on local practice and research protocols. Briefly, most of the participating centres used a combination of antiviral treatment (hydroxychloroquine or retrovirus inhibitor [lopinavir/ritonavir or remdesivir]), inflammation inhibitors (anti-interleukin 6, anti-interleukin 1, or corticosteroids) and empirical antibiotic treatment. Patients with confirmed SARS-CoV-2 pneumonia who required oxygen support and/or mechanical ventilation were systematically empirically treated with amoxicillin/clavulanate or ceftriaxone with macrolides.

### Table 1. Baseline characteristics of the patients according to SARS-CoV-2 infection status

| Characteristics                        | All (N = 237) | SARS-CoV-2 (n = 26) | Non-SARS-CoV-2 (n = 211) | P       |
|----------------------------------------|--------------|---------------------|--------------------------|---------|
| Age, years                             | 66.6 ± 13.8  | 62.7 ± 13.3         | 67 ± 13.8                | 0.13    |
| Male sex                               | 163 (68.8)   | 19 (73.1)           | 144 (68.2)               | 0.62    |
| Body mass index                        | 27 ± 4.7     | 28 ± 4.15           | 26.2 ± 4.7               | 0.07    |
| Arterial hypertension                  | 72 (30.4)    | 5 (19.2)            | 67 (31.7)                | 0.19    |
| Diabetes                               | 117 (49.4)   | 15 (57.7)           | 102 (48)                 | 0.36    |
| Dyslipidemia                           | 90 (38)      | 11 (42.3)           | 79 (37.4)                | 0.63    |
| eGFR < 50 mL/min/m²                    | 20 (8.4)     | 4 (15.4)            | 16 (7.6)                 | 0.17    |
| Respiratory disease                    | 21 (8.9)     | 4 (15.4)            | 17 (8.1)                 | 0.21    |
| Male sex                               | 163 (68.8)   | 19 (73.1)           | 144 (68.2)               | 0.62    |
| Body mass index                        | 27 ± 4.7     | 28 ± 4.15           | 26.2 ± 4.7               | 0.07    |
| Arterial hypertension                  | 72 (30.4)    | 5 (19.2)            | 67 (31.7)                | 0.19    |
| Diabetes                               | 117 (49.4)   | 15 (57.7)           | 102 (48)                 | 0.36    |
| Dyslipidemia                           | 90 (38)      | 11 (42.3)           | 79 (37.4)                | 0.63    |
| eGFR < 50 mL/min/m²                    | 20 (8.4)     | 4 (15.4)            | 16 (7.6)                 | 0.17    |
| Respiratory disease                    | 21 (8.9)     | 4 (15.4)            | 17 (8.1)                 | 0.21    |

Data are presented as n (%), mean ± SD, or mean [25%-75% quartile]. Bold values represent P < 0.05.

C-reactive protein, C-reactive protein; eGFR, estimated glomerular filtration rate by Modification of Diet in Renal Disease (MDRD) equation; STEMI, ST-elevation myocardial infarction.

* P value is given for contingency tables.

1 Available in only 74 patients (15 with and 59 without SARS-CoV-2 infection).
Clinical outcomes

The primary end point was in-hospital death. Secondary end points included in-hospital cardiac arrest, cardiogenic shock or heart failure, mechanical complications, and discharge left ventricular ejection fraction (LVEF).

Statistical analyses

SPSS 25 software (IBM Corp, Armonk, NY) was used for the statistical analyses. Nominal and categorical variables were expressed as frequency and percentages and compared using a $\chi^2$ test. Continuous variables were expressed as mean $\pm$ SD and/or in median and quartile (25%-75%) as appropriate. Comparisons between groups were performed with a Student $t$ test, a Z test, or 1-way analysis of variance if the validity conditions were met. If necessary, the normal distribution was assessed using a Kolmogorov-Smirnov test or a normality test. Continuous variables were expressed as mean $\pm$ SD or mean [25%-75% quartile]. Bold values represent $P < 0.05$.

Results

From April 1-22, 2020, two hundred thirty-seven patients (mean age, 67 $\pm$ 14 years; 69% male; Table 1) were included in the registry, of whom 49% (n = 116) were admitted for STEMI and 51% (n = 121) for NSTEMI. SARS-CoV-2 infection was reported in 26 patients (17 with STEMI and 9 with NSTEMI). Patients with SARS-CoV-2 were more frequently diabetic (54% vs 26%; $P = 0.003$) and tended to have greater body mass index (28 $\pm$ 4 vs 26 $\pm$ 5; $P = 0.07$; Table 1). The rate of ACS with SARS-CoV-2 infection was higher for Paris (19%) compared with the other centres (9% in the north of France and 7% in the south of France). Most patients with ACS with SARS-CoV-2 infection (54%) were directly admitted from home and 14 of 26 patients had unknown SARS-CoV-2 infection status on admission. Median time delay between first SARS-CoV-2 symptoms and ACS was 10 days (interquartile range, 6-15) and the SARS-CoV-2 pneumonia status during hospitalization period was graded as nonsevere for 11 (42%) patients, 8 of whom required invasive mechanical ventilation. Characteristics of SARS-CoV-2 patients are detailed in Supplemental Table S1. Overall, patients with ACS and SARS-CoV-2 infection had more severe clinical presentation with a higher incidence of cardiac arrest at admission (27% vs 7%; $P = 0.03$), higher C-reactive protein (53 mg/L [19-127 mg/L] vs 3 mg/L [2-8 mg/L]; $P < 0.001$) and D-dimer levels (1340 ng/mL [414-2983] vs 270 ng/mL [0-500 ng/mL]; $P < 0.001$), post procedure no-reflow (19% vs 3%; $P < 0.001$), greater in-hospital mortality (27% vs 7%; $P = 0.003$), and in-hospital cardiac arrest (46% vs 6%; $P < 0.001$).
Table 3. Characteristics of patients with NSTEMI according to SARS-CoV-2 infection status

|                      | All (N = 121) | SARS-CoV-2 (n = 9) | Non-SARS-CoV-2 (n = 112) | P  |
|----------------------|---------------|-------------------|--------------------------|----|
| Age, years           | 66.8 ± 13.9   | 61.6 ± 14.8       | 67.2 ± 13.8              | 0.24 |
| Male sex             | 84 (69)       | 7 (78)            | 77 (69)                  | 0.58 |
| Cardiac arrest at presentation | 3 (2.5) | 1 (11.1)           | 2 (1.8)                  | 0.08 |
| Nonobstructive coronary arteries | 16 (13.2) | 1 (11.1)           | 15 (13.4)                | 0.85 |
| Infarct related artery |              |                   |                         | 0.61*|
| Left main            | 6 (5.7)       | 0 (0)             | 6 (6.2)                  |     |
| Left anterior descending | 44 (41.9) | 5 (62.5)           | 39 (40.2)                |     |
| Left circumflex      | 24 (22.8)     | 1 (12.5)          | 23 (23.7)                |     |
| Right coronary artery | 31 (29.5) | 2 (25)             | 29 (29.9)                |     |
| Type of culprit lesion |            |                   |                         | 0.021*|
| Acute occlusion      | 19 (18)       | 4 (50)            | 15 (15.5)                |     |
| Stenosis > 50%       | 81 (77)       | 3 (37.5)          | 78 (80.4)                |     |
| Stenosis < 50%       | 5 (4.7)       | 1 (12.5)          | 4 (4.1)                  |     |
| Coronary anatomy     |              |                   |                         | 0.77*|
| Single-vessel disease | 31 (29.5) | 2 (25)             | 29 (29.9)                |     |
| Multivessel disease  | 37 (35.2)     | 6 (75)            | 69 (71.1)                |     |
| Procedural aspects   |              |                   |                         |     |
| Thrombosispiration   | 4 (3.8)       | 0 (0)             | 4 (4.1)                  | 0.56 |
| Stent PCI            | 89 (74.8)     | 7 (87.5)          | 80 (98.5)                | 0.07 |
| Any PCI (balloon or stent) | 92 (78.6) | 7 (87.5)           | 83 (95.6)                | 0.88 |
| Anti-GP IIb/IIa use  | 5 (4.7)       | 2 (25)            | 3 (3.1)                  | 0.049|
| Persistent no-reflow | 4 (3.8)       | 1 (12.5)          | 3 (3.3)                  | 0.19 |
| Outcome (all NSTEMI patients) |     |                   |                         |     |
| In-hospital death    | 5 (4.1)       | 0 (0)             | 5 (4.5)                  | 0.52 |
| In-hospital cardiac arrest | 8 (6.6) | 3 (33.3)           | 5 (4.5)                  | 0.007|
| Cardiogenic shock or heart failure | 16 (13.2) | 2 (22.2)          | 14 (12.5)                | 0.41 |
| LVEF on discharge, % | 52 ± 11       | 48 ± 10           | 53 ± 11                  | 0.24 |
| Median peak Hs troponin, ng/L | 443 [131-1269] | 605 [311-2631]  | 441 [120-1256]           | 0.26 |
| Median C-reactive protein, mg/L | 3.3 [2-15] | 68.1 [46-115]     | 3.0 [2-8]                | < 0.001|

Data are presented as n (%), mean ± SD, or mean [25%-75% quartile]. Bold values represent P < 0.05.

C-reactive protein, C-reactive protein; GP, glycoprotein; Hs, high-sensitivity; LVEF, left ventricular ejection fraction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention.

* P value is given for contingency tables.

STEMI

The initial admission pathway for STEMI was the French emergency structure (SAMU, n = 80; 72%), emergency department (n = 13; 12%), and in- or interhospital transfer (n = 18; 16%; Table 2). All patients underwent primary PCI and no thrombolytic therapy was administered. Time delay from symptom onset to reperfusion was 4 hours [0-48], with no difference between Paris (median, 3 hours [2-9]) and the other centres and between SARS-CoV-2 and no SARS-CoV-2 infection (3 hours [2-48] vs 4 hours [2-48]; P = 0.62). However, cardiac arrest or severe ventricular arrhythmia at admission was more prevalent in patients with SARS-CoV-2 infection (55% vs 12%; P = 0.015; Table 2). Aspirin was administered in 100% of STEMI patients irrespective of SARS-CoV-2 status. Administration of P2Y12 inhibitors (82% vs 92%), heparin (82% vs 92%; P = 0.1), and GP IIb/IIa inhibitors (84.6% vs 87.8%; P = 0.75) did not differ in SARS-CoV-2 infected and noninfected patients. Normal coronary angiogram was reported in 4 of 17 (24%) patients with STEMI and SARS-CoV-2 infection. In patients with significant coronary artery disease (n = 17), 9 of 17 (53%) had single-vessel disease. Complete culprit artery occlusion was more frequently observed in STEMI patients with than without SARS-CoV-2 infection (98% vs 69%; P < 0.05). PCI was similarly performed regardless of infection status (85% in SARS-CoV-2 vs 88% in non-SARS-CoV-2 infection; P = 0.75) but angiographic no-reflow was more frequently observed after PCI in patients with SARS-CoV-2 infection (31% vs 4%; P < 0.001). Despite lower peak troponin levels and similar LVEF, cardiac arrest (53% vs 7%; P < 0.0001) and heart failure during the hospitalization (47% vs 22%; P = 0.003) were more frequent in patients with STEMI and SARS-CoV-2 infection. Finally, the mortality rate was greater in STEMI patients with than without SARS-CoV-2 infection (41% vs 8%; P < 0.001). The causes of death in STEMI patients with SARS-CoV-2 infection were cardiac arrest (n = 3), refractory arrhythmia (n = 1), and pneumonia related to SARS-CoV-2 (n = 3; Supplemental Table S1).

NSTEMI

SARS-CoV-2 infection was reported in 9 of 121 (7.4%) patients admitted for NSTEMI. Patients with NSTEMI with and without SARS-CoV-2 infection had similar age and sex distribution (Table 3). Similar to the STEMI population, cardiac arrest on presentation tended to be more frequent in patients with SARS-CoV-2 infection (11% vs 2%; P = 0.08). No differences were observed in ACS treatment between the SARS-CoV-2 and non-SARS-CoV-2 group (89% vs 92% for aspirin; 78% vs 80% for P2Y12 inhibitors; and 67% vs 77% for heparin). However, GP IIb/IIa inhibitors were used more frequently in patients with NSTEMI with than without SARS-CoV-2 (25% vs 3%; P = 0.05). Nonobstructive coronary artery disease was reported in only 1 NSTEMI patient.
with SARS-CoV-2 infection. In NSTEMI patients with significant coronary lesions, occlusion of the culprit artery was more frequent in patients with SARS-CoV-2 infection (50% vs 16%; \( P = 0.015 \)). PCI rate was similar in the 2 groups. Cardiac troponin levels and LVEF were similar in the 2 groups. In-hospital cardiac arrest (33% vs 5%; \( P = 0.007 \)) was more frequent in patients with NSTEMI and SARS-CoV-2 infection but no death was reported in patients with NSTEMI and SARS-CoV-2 infection (Table 3 and Supplemental Table S1).

Myocardial infarction with nonobstructive coronary arteries

Myocardial infarction with nonobstructive coronary arteries (n = 21) was reported in 5 of 26 (19%) patients with and 16 of 211 (7.6%) patients without SARS-CoV-2 infection (\( P < 0.0001 \)). Of the 5 patients with SARS-CoV-2 infection, 1 had NSTEMI and 4 had STEMI presentations (Supplemental Table S1). Specific etiology was identified in 2 patients (1 takotsubo syndrome and 1 of embolic origin from native aortic valve thrombosis). The 2 deaths in the myocardial infarction with nonobstructive coronary arteries group occurred exclusively in patients with SARS-CoV-2 infection, both as the result of acute respiratory distress syndrome.

In-hospital death

Mortality rates were higher in patients with ACS and SARS-CoV-2 infection (26.9% vs 13%; \( P = 0.0003 \)). In univariate analysis, clinical and angiographic factors associated with in-hospital death were SARS-CoV-2 infection (odds ratio [OR], 5.6 [95% confidence interval (CI), 1.99-15.7]; \( P = 0.0011 \)), no-reflow (OR, 15 [95% CI, 4.2-52.8]; \( P < 0.001 \)), cardiac arrest on presentation (OR, 7.8 [95% CI, 2.68-22.68]; \( P = 0.002 \)), STEMI (OR, 3.4; [95% CI, 1.2-9.8]; \( P = 0.02 \)), and diabetes (OR, 2.7 [95% CI, 1.085-6.9]; \( P = 0.03 \)). In multivariate analysis, independent variables were diabetes, no-reflow and cardiac arrest on presentation whereas SARS-CoV-2 was not because SARS-CoV-2 was the only variable associated with no-reflow (OR, 6.3 [95% CI, 1.7-23]; \( P = 0.05 \)) and cardiac arrest on presentation.

Discussion

This multi centre registry conducted in April during the SARS-CoV-2 epidemic plateau in France showed a significant prevalence of SARS-CoV-2 infection in ACS patients (19% for Paris, 11% for overall). ACS with concomitant SARS-CoV-2 infection was characterized by a more severe initial clinical presentation with greater percentage of cardiac arrest on admission, occluded culprit lesion, and no-reflow after PCI. This resulted in a higher in-hospital mortality and increased complications.

STEMI and SARS-CoV-2

In a comparison of STEMI patients with and without SARS-CoV-2 infection, there was no significant difference in time from symptom onset to revascularization. Also, compared with the data of the French registry on ACS, French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI), the pandemic did not seem to influence the median time from symptom onset to revascularization (4 hours vs 3.8 hours).\(^{14,15}\) This lack of difference was probably because of the efficient reinforcement of the SAMU during the epidemic crisis. In terms of coronary anatomy, SARS-CoV-2 patients had myocardial infarction with nonobstructive coronary arteries more frequently but most had obstructive coronary artery disease with a high prevalence of an acutely occluded culprit artery in STEMI and NSTEMI patients. This might explain the high proportion of cardiac arrest in this population.

SARS-CoV-2 and thrombotic burden

The high incidence of no-reflow phenomenon after PCI suggests a high thrombotic burden in the culprit lesion and raises the question of GP IIb/IIIa inhibitors use with or without cytokine inhibitors to block the cytokine storm and the inflammation-related coagulopathy. Our data are in agreement with the retrospective study performed by Choudry et al., showing that COVID-19 infection in patients with STEMI was associated with a higher thrombus burden, increased need to use GP IIb/IIIa inhibitors, and mortality.\(^{15}\) The main hypothesis to explain this phenomenon is the procoagulant state induced by SARS-CoV-2 infection due to endothelial and/or platelet dysfunction and associated with disseminated intravascular coagulation secondary to severe inflammation. Such a hypothesis is also consistent with recent literature data on various thrombotic events and complications among SARS-CoV-2 patients.\(^{16,17}\)

SARS-CoV-2 and mortality

Consistently, patients with STEMI and SARS-CoV-2 infection had a dramatically higher in-hospital mortality (42.1%) than patients with STEMI without SARS-CoV-2 infection (8.1%). These rates are also higher than those reported in the FAST-MI registry (approximately 2.8%) because patients with ACS with early death were excluded from the FAST-MI registry. It might be tempting to consider that the excess mortality in patients with ACS and concomitant SARS-CoV-2 infection is driven by the respiratory infection but our present registry shows that hemodynamic complications (cardiac arrest and heart failure) were highly prevalent in the SARS-CoV-2 group and that independent variables associated with death were cardiac arrest at presentation and no-reflow. Almost half (43%; n = 3 of 7) of the deaths in the SARS-CoV-2 group had nonsevere respiratory infection and died of cardiovascular complications.

Altogether, these data underline the importance of referring most patients with ACS and SARS-CoV-2 infection to coronary angiogram, because the large proportion of patients with STEMI and concomitant SARS-CoV-2 infection had a significant coronary lesion that could be treated with PCI. These findings are also consistent in the NSTEMI population because 90% of patients in the SARS-CoV-2 group had significant coronary disease with a high proportion of culprit artery occlusion. The low proportion of NSTEMI in SARS-CoV-2 patients is possibly related to the fact that SARS-CoV-2 patients with NSTEMI are under-reported and usually not referred for a coronary
angiogram. An increase in cardiac biomarkers has been considered a sign of myocardial injury related to systemic inflammation, cytokine storm, or other immunologic mechanisms. However, because of the high rate of significant coronary thrombosis, coronary angiogram should be systematically considered, especially in patients with hemodynamic instability.

Limitations

Although significant data from multiple centres were gathered in this registry in a very short period of time, the sample size remains small. Larger studies are needed to precisely describe the relationship between SARS-CoV-2 infection, ACS occurrence, and prognosis. Moreover, the prevalence of SARS-CoV-2-related ACS might be overestimated for 2 reasons. First, some of the participating hospitals were reference centres for the SARS-CoV-2 infection, in regions with high prevalence during the study period. Second, published data from regions with a high SARS-CoV-2 prevalence suggest a significant decrease in ACS-related hospitalizations during the pandemic. The effect of SARS-CoV-2 in the overall ACS prevalence in the corresponding population was beyond the scope of this study.

Conclusion

SARS-CoV-2 infection is frequent in patients managed for ACS (11%) especially in regions with high prevalence of SARS-CoV-2 infection. Patients with SARS-CoV-2 infection and ACS have a high prevalence of occluded artery and no-reflow phenomenon, which suggests high thrombotic burden that could explain, in part, higher rates of in-hospital complications and mortality. Further studies are needed to elucidate the mechanisms and the optimal management of coronary thrombosis in SARS-CoV-2 patients.

Funding Sources

The authors have no funding sources to declare.

Disclosures

The authors have no conflicts of interest to disclose.

References

1. Zhou P, Yang XL, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
2. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81.
3. Studiero F, Silverio A, Di Maio M, et al. Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thromb Res 2020;198:34-9.
4. Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiol Cardiothorac Imaging 2020;2:e200067.
5. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA 2020;5:802-10.
6. Akhmerov A, Marban E. COVID-19 and the heart. Circ Res 2020;126:1443-55.
7. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:811-8.
8. Bangalore S, Sharma A, Slotwiner A, et al. ST-segment elevation in patients with Covid-19 — a case series. N Engl J Med 2020;382:2478-80.
9. Agwall S, Antunes MJ, Bucciarelli-Ducci C, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018;39:119-77.
10. Stefanini GG, Montorfano M, Trabattoni D, et al. ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation 2020;14:2113-6.
11. Thysesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019;40:237-60.
12. Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.
13. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med 1985;312:932-6.
14. Puymirat E, Simon T, Cayla G, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation 2017;136:1908-19.
15. Choudry FA, Hamshere SM, Rathod KS, et al. High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2020;76:1168-76.
16. Lushina N, Kuo JS, Shaikh HA. Pulmonary, cerebral, and renal thromboembolic disease associated with COVID-19 infection. Radiology 2020;296:E181-3.
17. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145-7.
18. Belle L, Cayla G, Cotin Y, et al. French registry on Acute ST-elevation and non–ST-elevation Myocardial Infarction 2015 (FAST-MI 2015). Design and baseline data. Arch Cardiovasc Dis 2017;110:366-78.
19. De Filippo O, D’Ascenzo F, Angelini F, et al. Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med 2020;383:88-9.

Supplementary Material

To access the supplementary material accompanying this article, visit CJC Open at https://www.cjcopen.ca/ and at https://doi.org/10.1016/j.jcjco.2020.11.003.